$HIMS is shaking up the pharma space, challenging $NVO’s patents in a high-stakes bet that could disrupt the weight loss market. Both $NVO and $LLY face significant downside risk if litigation goes against them, making this a fascinating clash between nimble disruptors and Big Pharma. Meanwhile, $MGM is quietly reducing its float, repurchasing 5.5% of shares in a single quarter, signaling confidence amid broader market volatility. Investors should watch legal battles and corporate capital moves alike for asymmetric opportunities. 1. $Hims & Hers Health Inc.(HIMS)$ My gut feeling is that $HIMS is playing the ultimate disruption card. They’re pushing so hard Novo sues, which ultimately leads to Novo defending — and potentially invalidating — the